FGI-101-1A6: Phase Ia data

A double-blind, placebo-controlled Phase Ia trial in 48 healthy volunteers showed that single ascending-doses of FGI-101-1A6 were tolerated. Patients received placebo or 1 of 6 doses of IV FGI-101-1A6...